Aisling Capital Management’s Arcus Biosciences RCUS Stock Holding History

Aisling Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-333,333	Closed	-$4.63M	–	14
2020 Q1	$4.63M	Hold	333,333	–	–	2.02%	7
2019 Q4	$3.37M	Hold	333,333	–	–	1.29%	10
2019 Q3	$3.03M	Hold	333,333	–	–	1.58%	11
2019 Q2	$2.65M	Hold	333,333	–	–	1.13%	12
2019 Q1	$4.16M	Sell	333,333 -203,180	-38%	-$2.21M	3.17%	10
2018 Q4	$5.78M	Buy	+536,513	New	+$6.26M	6.09%	7

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Aisling Capital Management's RCUS Position: Q2 2020 in Review

Aisling Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2020, closing a stake of 333,333 shares — an estimated $4.63M sold.

Aisling Capital Management first reported a position in RCUS in Q4 2018 and held it in 6 quarters. The position peaked at $5.78M in Q4 2018. 139 funds tracked by Wall St. Rank hold RCUS as of Q2 2020.

Aisling Capital Management reported no remaining Arcus Biosciences position as of Q2 2020 after selling out during the quarter.
Aisling Capital Management sold 333,333 Arcus Biosciences shares in Q2 2020, an estimated $4.63M.
Aisling Capital Management first reported a position in Arcus Biosciences in Q4 2018 and held it in 6 quarters.
Aisling Capital Management's Arcus Biosciences position peaked at $5.78M in Q4 2018.
139 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2020.

Based on Aisling Capital Management's 13F filing for Q2 2020, filed 10 Aug 2020.